Alto Neuroscience Completes Enrollment in Phase 2 Trial for Schizophrenia Cognitive Impairment Treatment
Event summary
- Alto Neuroscience has completed enrollment in its Phase 2 proof-of-concept trial for ALTO-101, a transdermal PDE4 inhibitor targeting cognitive impairment associated with schizophrenia (CIAS).
- The study enrolled 83 patients across 13 U.S. clinical sites and is designed as a randomized, double-blind, placebo-controlled crossover trial.
- Topline data from the study is expected by the end of Q1 2026 and will guide future development decisions for ALTO-101.
- ALTO-101 has received Fast Track Designation from the U.S. FDA for this indication.
The big picture
Alto Neuroscience's completion of enrollment in this Phase 2 trial represents a critical step in addressing a significant unmet medical need in schizophrenia treatment. Cognitive impairment is a core feature affecting nearly all patients with schizophrenia, yet there are currently no approved pharmacologic treatments. The success of ALTO-101 could position Alto as a leader in precision psychiatry, leveraging its biomarker-driven approach to develop targeted therapies for neuropsychiatric disorders.
What we're watching
- Clinical Efficacy
- How the topline data from this Phase 2 trial will impact the future development trajectory of ALTO-101.
- Regulatory Pathway
- Whether the Fast Track Designation will accelerate ALTO-101's path to potential approval for CIAS.
- Market Differentiation
- The pace at which Alto can establish ALTO-101 as a first-of-its-kind treatment in the absence of approved therapies for CIAS.
Our editorial coverage:
Related topics